Integrated Network Pharmacology and In-Silico Molecular Docking Studies to Unveil Mechanism of Action of Polyphenolic Compounds of Psidium Guajava for The Management of Thrombocytopenia

Despite considerable studies, thrombocytopenia is still affecting millions of people with an increasing rate of morbidity and mortality around the globe. Therefore, we aimed to identify pharmacologically active polyphenolic compounds such as quercetin, apigenin and kaempferol in Psidium guajava for...

Full description

Bibliographic Details
Main Authors: Adil Ahamad, Kamran Javed Naquvi, Mohd. Javed Naeem, Javed Ahamad, S. H. Ansari, Sayeed Ahmad
Format: Article
Language:English
Published: Tishk International University 2022-12-01
Series:Eurasian Journal of Science and Engineering
Subjects:
Online Access:https://eajse.tiu.edu.iq/index.php/volume-8-issue-3-article-22/
Description
Summary:Despite considerable studies, thrombocytopenia is still affecting millions of people with an increasing rate of morbidity and mortality around the globe. Therefore, we aimed to identify pharmacologically active polyphenolic compounds such as quercetin, apigenin and kaempferol in Psidium guajava for the management of thrombocytopenia using network pharmacology and in-silico molecular docking. The results of ADME/Tox screening revealed that all the polyphenolic compounds possess the drug-likeness activity and were found safe. Moreover, network pharmacology revealed that polyphenolic compounds of Psidium guajava may combat diabetes by acting on key targets, such as MAPK, TP53 and TNF-α which were strongly involved in oxidative stress, inflammatory responses and blood-related parameters involved in thrombocytopenia. Further, a mechanistic approach through molecular docking also supports the strong binding sites of quercetin, apigenin and kaempferol. Conclusively, in-silico ADME, molecular docking and network pharmacology study revealed that identified compounds are safe and pharmacologically effective. These identified compounds could be a great source for the development of new anti-thrombocytopenic drugs in the future.
ISSN:2414-5629
2414-5602